Text Size

Expression Levels of microRNA Processing Enzymes Dicer and Drosha in Epithelial Skin Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael Sand, Ruhr University of Bochum
ClinicalTrials.gov Identifier:
NCT00849914
First received: February 20, 2009
Last updated: October 15, 2012
Last verified: October 2012
History of Changes
  Purpose

MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study the expression profiles for the two most important miRNA processing enzymes Dicer and Drosha of actinic keratoses, basal cell carcinoma and squamous cell carcinoma are compared to healthy skin tissue.


Condition
Skin Cancer

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Expression Levels of microRNA Processing Enzymes Dicer and Drosha in Epithelial Skin Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Skin Cancer
U.S. FDA Resources

Further study details as provided by Ruhr University of Bochum:

Biospecimen Retention:   Samples With DNA

Punch biopsy from tumour, punch biopsy from healthy skin


Enrollment: 28
Study Start Date: July 2008
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Patients with actinic keratoses of the skin
2
Patients with basal cell carcinoma of the skin
3
Patients with squamous cell carcinoma of the skin

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

dermatologic primary care clinic

Criteria

Inclusion Criteria:

  • Patients with actinic keratoses, squamous cell carcinoma or basal cell carcinoma of the skin

Exclusion Criteria:

  • Patients under 18 years of age
  • Patients with other forms of cancer in previous medical history
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00849914

Locations
Germany
Department of Dermatology and Allergology, Ruhr-University Bochum
Bochum, Germany, 44791
Sponsors and Collaborators
Ruhr University of Bochum
Investigators
Principal Investigator: Prof. Dr. Peter Altmeyer Department of Dermatology and Allergology, Ruhr-University Bochum
  More Information

Publications:

Responsible Party: Michael Sand, Dr., Ruhr University of Bochum
ClinicalTrials.gov Identifier: NCT00849914     History of Changes
Other Study ID Numbers: 005
Study First Received: February 20, 2009
Last Updated: October 15, 2012
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Skin Neoplasms
Neoplasms by Site
Neoplasms
Skin Diseases

ClinicalTrials.gov processed this record on June 18, 2013